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ABSTRACT
CONTEXT AND OBJECTIVE: Dimethylarginine dimethylaminohydrolase enzymes (DDAH), which are en-
coded by the genes DDAH1 and DDAH2, play a fundamental role in maintaining endothelial function. 
We  conducted a case-control study on a Chinese population that included three ethnic groups (Han, 
Kazakh and Uygur), to systemically investigate associations between variations in the genes DDAH1 and 
DDAH2 and hypertension. 
DESIGN AND SETTING: Experimental study at the Department of Internal Medicine and Genetic Diagno-
sis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. 
METHODS: This case-control study included 1,224 patients with hypertension and 967 healthy unrelated 
individuals as controls. DDAH1 -396 4N (GCGT) del>ins, rs3087894, rs805304 and rs9267551 were geno-
typed using the TaqMan 5’ nuclease assay.
RESULTS: The G/C genotype of rs3087894 in DDAH1 was a risk factor for hypertension in the Kazakh group 
in the co-dominant model (G/C versus G/G) (OR 1.39; 95% CI: 1.02-1.88; P < 0.05), with the same result in 
the dominant model (G/C + C/C versus G/G) (OR 1.38; 95% CI: 1.03-1.84; P < 0.05). In contrast, the C/C 
genotype of rs3087894 seemed to be a protective factor against hypertension in the Uygur group in the 
recessive model (C/C versus G/G + G/C) (OR 0.62; 95% CI: 0.39- 0.97; P < 0.05). Similar findings for rs3087894 
were also observed after adjusting the variable for the age covariate. 
CONCLUSION: Our results indicated that the C-allele of rs3087894 in DDAH1 was a risk factor for hyperten-
sion in the Kazakh group but a protective factor in the Uygur group.
RESUMO 
CONTEXTO E OBJETIVO: Enzimas dimetilarginina dimetilaminohidrolase (DDAH), codificadas por genes 
DDAH1 e DDAH2, desempenham papel fundamental na manutenção da função endotelial. Realizamos 
estudo tipo caso-controle na população chinesa, com três grupos étnicos (han, kazakh e uygur) para in-
vestigar sistematicamente a associação entre a variação de genes DDAH1 e DDAH2 e a hipertensão. 
DESENHO E LOCAL: Estudo tipo caso-controle no Departamento de Medicina Interna e Diagnóstico Ge-
nético, Hospital de Tongji, Tongji Medical College, Universidade de Ciência e Tecnologia de Huazhong. 
MÉTODOS: Este estudo incluiu 1.224 pacientes com hipertensão e 967 indivíduos saudáveis, sem pa-
rentesco, como controles. DDAH1 -396 4 N (GCGT) del > ins, rs3087894, rs805304 and rs9267551 foram 
genotipados usando o ensaio nuclease TaqMan 5’. 
RESULTADOS: O genótipo G/C de rs3087894 no DDAH1 foi um fator de risco para a hipertensão arterial 
no grupo kazakh em modelo codominante (G/C versus G/G; OR 1,39; IC 95%: 1,02-1,88; P < 0,05), com 
o mesmo resultado no modelo dominante (G/C + C/C versus G/G; OR 1,38; IC 95%: 1,03-1,84; P < 0,05). 
Em contraste, o genótipo C/C de rs3087894 parecia ser um fator de proteção para a hipertensão no grupo 
uygur no modelo recessivo (C/C versus G/G + G/C; OR 0,62; IC 95%: 0,39-0,97; P < 0,05). Achado semelhante 
para rs3087894 também foi observado depois de se ajustar a variante à covariante idade.
CONCLUSÃO: Os nossos resultados indicaram que o C-alelo de rs3087894 no DDAH1 foi fator de risco 
para a hipertensão no grupo de kazakh, mas fator de proteção no grupo de uygur. 
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INTRODUCTION
Raised blood pressure (BP) or hypertension is a multifactorial 
disorder and a major risk factor for stroke and ischemic heart dis-
ease. The World Health Organization has estimated that hyper-
tension affects over one billion people and that will rise to 1.5 bil-
lion by 2020, thus contributing 13.5 million deaths worldwide 
annually.1-3 Hypertension is a complex trait influenced by genetic 
or environmental factors (including age, weight, ethnicity and 
diet), or their interactions.4-8 Many studies have demonstrated 
that estimates of heritability of BP range from 31% to 68%,9-11 
and this has prompted extensive efforts to identify genes associ-
ated with hypertension. A legible genetic map of hypertension 
will highlight potential drug targets for its prevention or treat-
ment and reduce the risk of cardiovascular events among peo-
ple with hypertension.12,13 A large number of candidate genes for 
hypertension have now been widely studied and, among these, 
the genes DDAH1 and DDAH2 seem to have an influence on 
hypertension, since they play a fundamental role in maintaining 
endothelial function.14-16
Dimethylarginine dimethylaminohydrolase enzymes (DDAH), 
which are encoded by the genes DDAH1 and DDAH2, clear asym-
metric dimethylarginine (ADMA) from the kidneys and liver.17 
ADMA, as an endogenous inhibitor of nitric oxide (NO) synthase, 
reduces NO and thus regulates endothelial function. Based on detec-
tion of endothelial dysfunction at the origin of hypertension, ADMA 
has considerable clinical impact on hypertension. Studies have dem-
onstrated that DDAH1 variants are associated with increased plasma 
ADMA and increased risk of thrombosis, stroke and coronary artery 
disease (CAD) in humans.18,19 Similarly, Leiper et al. have shown that 
loss of DDAH1 activity leads to accumulation of ADMA and reduc-
tion in NO signaling, which in turn causes vascular pathophysiol-
ogy, including endothelial dysfunction, increased systemic vascular 
resistance and elevated systemic and pulmonary blood pressure.20
OBJECTIVE
In view of the genetic heterogeneity among ethnic groups, in 
the present study we aimed to systemically evaluate associations 
between the DDAH1 and DDAH2 variants and hypertension in 




This case-control study included 1,224 patients with hyperten-
sion (660 males and 564 females; mean age 55.90 ± 11.23 years) 
who had histories of hypertension (systolic BP ≥ 140 mmHg and/
or diastolic BP ≥ 90 mmHg) or histories of use of anti-hyperten-
sion medication such as calcium channel blockers, beta-blockers, 
angiotensin receptor blockers, angiotensin-converting enzyme 
inhibitors or diuretics. Patients with kidney disease (glomerular 
filtration rate, GFR, of less than 60 ml/minute) were excluded from 
the study. In addition, a group of 967 healthy unrelated individu-
als (504 males and 463 females; mean age 51.62 ± 13.50) without 
hypertension was studied as a control group. The control group 
was initially recruited in the same study and was matched to cases 
according to race, geographic location and date of data-gather-
ing (within three months). Individuals from three ethnic groups 
(Han, Kazakh and Uygur) who came to Shihezi hospital or outpa-
tient clinic, in Xinjiang province, China, between January 2013 and 
December 2013, were recruited. All participants signed an informed 
consent statement. This study was approved by the Medical Ethics 
Committee of the hospital and the study protocol conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki. 
All participants underwent standard medical history-taking 
and physical evaluations. They answered a questionnaire that sought 
complete demographic information (name, age, sex, smoking, 
drinking, history of disease and so on). A complete general physical 
examination was carried out. BP was measured in a sitting position 
using a standard analogue sphygmomanometer. Plasma glucose, 
lipid and homocysteine levels were measured using standard meth-
ods, using an Olympus AU 2700 automatic biochemical analyzer 
(Olympus CO Ltd., Tokyo, Japan), after the patients had fasted for 
12 h overnight.
DNA extraction and genotyping
Genomic DNA from whole blood containing EDTA was isolated 
using a DNA isolation kit (Tiangen Biotech, Beijing, China), in 
accordance with the protocol. DDAH1 -396 4N (GCGT) del>ins, 
c.17 G > C (rs3087894), DDAH2 c.531 A > C (rs805304) and c.662 
G > C (rs9267551) were genotyped using the TaqMan 5’ nucle-
ase assay in the 7900HT fast real-time PCR system, using primers 
and probes synthesized by ABI (Applied Biosystems, Foster City, 
CA, USA), under standard conditions.21 The sequences of probes 
and primers for DDAH1 -396 4N (GCGT) del>ins were as fol-
lows: forward primer, 5’ CAGGTAAAGACCAGGAAGCCC 3’; 
reverse primer, 5’ GGACCTCGGCGAAAAGC 3’; probe 1 del, 5’ 
CGCAGGTGCACAC 3’; and probe 2 ins, 5’ AGGTGCACGCACAC 
3’. The product codes of the other TaqMan probes were, in turn, 
C_2518300_10, C_3233671_10 and C_27848488_10. 
Statistical analysis
Continuous variables were shown as mean values, with their 
standard deviation and categorical variables expressed as abso-
lute numbers with their prevalence. The Kolmogorov-Smirnov 
test was used to evaluate departure from normal distribution, 
and this was evaluated for all continuous variables. The inde-
pendent-sample t test and Pearson’s chi-square test were applied 
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in order to observe the differences between patient and control 
groups for continuous variables and categorical variables, respec-
tively. The data relating to genotype frequencies of DDAH1 and 
DDAH2 variants in the patients and controls were obtained by 
means of direct counting, and significant differences among 
ethnic subgroups were assessed using Pearson’s chi-square test 
or Fisher’s exact test. The Hardy-Weinberg equilibrium was 
evaluated using Pearson’s chi-square test in order to determine 
the variation in distribution of alleles and genotypes within the 
study population. Inheritance hypotheses were tested in accor-
dance with three models: co-dominant, dominant and recessive. 
Binary  logistic regression was built to determine associations 
between the DDAH1 and DDAH2 variants and hypertension. 
All statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS Inc., Chicago, IL, USA), 
version 17.0. Double-sided P-values < 0.05 were considered sta-
tistically significant.
RESULTS
Characteristics of the study population
This case-control study recruited 1,224 patients with hyperten-
sion and 967 controls. Clinical information was collected at base-
line from all subjects and was compared between patients and 
controls. The clinical characteristics and laboratory test data are 
shown in Table 1. No differences relating to sex, ethnicity, smok-
ing or drinking were found between the patient and control groups 
(P > 0.05). The mean age of the patients was significantly higher 
than that of the controls (55.90 ± 11.23 versus 51.62 ± 13.50; P < 
0.01). The histories of CAD, stroke and diabetes differed signifi-
cantly between patients and controls (P < 0.05). In contrast with 
the controls, systolic BP, diastolic BP and body mass index were 
clearly higher among the patients. Moreover, the glucose, triglyc-
eride, total cholesterol, low-density lipoprotein cholesterol, apo-
lipoprotein B and homocysteine levels were significantly higher 
among the patients (P < 0.05). There were no differences between 
the two groups regarding apolipoprotein A1 and high-density 
lipoprotein cholesterol.
Genotype distribution in the three ethnic groups
Before analyzing gene variation in relation to hypertension, it 
was noteworthy that the genetic background was markedly dif-
ferent between the ethnic groups. Based on the TaqMan results, 
we determined and recorded the genotype of each individual 
and calculated the genotype and allele frequencies of each vari-
ation (DDAH1 -396 4N de l > ins, c.17 G > C, DDAH2 c.531 
A  > C and c.662 G > C) manually for the Han, Kazakh and 
Uygur groups (Table 2). The genotype distribution of the four 
variations was in line with the Hardy-Weinberg equilibrium 
Table 1. Baseline characteristics of patients and controls 
*indicates P-value < 0.01; †indicates P-value < 0.05; CAD = coronary artery disease; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; BMI = body mass index; 
LDL-c = low-density lipoprotein cholesterol; HDL-c = high-density lipoprotein cholesterol.
Variables Patients (n = 1224) Controls (n = 967) P-value
Female 46% 48% 0.355
Age 55.90 ± 11.23* 51.62 ± 13.50 0.000
Ethnic group -
Han 31% 30% -
Kazakh 35% 35% -
Uygur 34% 35% 0.828
Smoking 18% 19% 0.528
Drinking 21% 23% 0.148
History of CAD 34%* 14% 0.000
History of stroke 4%† 2% 0.009
History of diabetes 15%* 5% 0.000
SBP (mmHg) 149.46 ± 18.97* 119.14 ±10.19 0.000
DBP (mmHg) 91.46 ± 12.41* 75.92 ± 6.82 0.000
BMI (kg/m2) 26.62 ± 3.99* 25.55 ± 4.17 0.000
Glucose (mmol/l) 5.47 ± 1.95* 4.91 ± 1.30 0.000
Triglyceride (mmol/l) 1.50 ± 1.06* 1.30 ± 0.99 0.000
Total cholesterol (mmol/l) 4.92 ± 1.14* 4.60 ± 1.00 0.000
LDL-c (mmol/l) 2.84 ± 0.82* 2.70 ± 0.91 0.000
HDL-c (mmol/l) 1.46 ± 0.47 1.43 ± 0.46 0.154
Apolipoprotein A1 (g/l) 1.42 ± 0.29 1.39 ± 0.29 0.089
Apolipoprotein B (g/l) 0.96 ± 0.36* 0.89 ± 0.25 0.000
Homocysteine (μmol/l) 14.89 ± 7.34† 12.50 ± 7.37 0.037
Genotype Han Kazakh Uygur P-value
DDAH1 -396 4N (GCGT) del>ins
del/del 512 (0.78) 491 (0.65) 511 (0.68)
del/ins 135 (0.21) 245 (0.32) 209 (0.28)
ins/ins 9 (0.01) 23 (0.03) 31(0.04) 0.000 
MAF 0.12 0.19 0.18
DDAH1 c.17 G>C (rs3087894)
G/G 425 (0.65) 367 (0.49) 389 (0.52)
G/C 195 (0.30) 309 (0.41) 281 (0.37)
C/C 37 (0.06) 78 (0.10) 85 (0.11) 0.000 
MAF 0.20 0.31 0.30 
DDAH2 c.531 A>C (rs805304)
A/A 220 (0.33) 242 (0.32) 233 (0.31)
A/C 334 (0.50) 360 (0.48) 400 (0.54)
C/C 108 (0.16) 150 (0.20) 114 (0.15) 0.089 
MAF 0.42 0.44 0.42
DDAH2 c.662 G>C (rs9267551)
G/G 629 (0.95) 678 (0.90) 701 (0.93)
G/C 33 (0.05) 74 (0.10) 52 (0.07)
C/C 0 (0.00) 3 (0.00) 0 (0.00) 0.001 
MAF 0.03 0.05 0.03
Table 2. Genotype distribution of DDAH1 and DDAH2 polymorphisms 
in Han, Kazakh and Uygur groups
Data are shown as genotype number (proportion of genotype). P-values were 
obtained from comparisons between the three ethnic groups using Pearson’s 
chi-square test. MAF = minor allele frequency.
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Table 3. Odds ratios of DDAH variation in relation to hypertension in the Han, Kazakh and Uygur groups
Data are shown as odds ratio (with 95% confidence intervals). Data in bold and italic are binary logistic results between case-control groups that showed 
statistically significant differences (P < 0.05).
Inheritance model Han Kazakh Uygur Total
Genotype n = 668 n = 760 n = 761 n = 2191
DDAH1 -396 4N (GCGT) del>ins
co-dominant
del/del 1 1 1 1
del/ins 0.89 (0.61-1.30) 1.14 (0.83-1.55) 1.07 (0.77-1.47) 1.04 (0.86-1.26)
ins/ins 2.64 (0.54-12.82) 2.42 (0.94-6.23) 0.76 (0.37-1.56) 1.30 (0.78-2.19)
dominant
del/del 1 1 1 1
del/ins + ins/ins 0.94 (0.65-1.37) 1.21 (0.89-1.63) 1.02 (0.75-1.39) 0.99 (0.83-1.19)
recessive
del/del + del/ins 1 1 1 1
ins/ins 2.70 (0.56-13.12) 2.32 (0.90-5.94) 0.74 (0.36-1.52) 1.07 (0.86-1.35)
DDAH1 c.17 G>C (rs3087894)
co-dominant
G/G 1 1 1 1
G/C 0.96 (0.68-1.35) 1.39 (1.02-1.88) 1.09 (0.80-1.49) 1.14 (0.95-1.37)
C/C 1.01 (0.51-1.99) 1.35 (0.82-2.22) 0.64 (0.40-1.03) 0.92 (0.68-1.24)
dominant
G/G 1 1 1 1
G/C + C/C 0.96 (0.70-1.33) 1.38 (1.03-1.84) 0.97 (0.73-1.29) 1.09 (0.92-1.29)
 recessive
G/G + G/C 1 1 1 1
C/C 1.03 (0.53-2.00) 1.17 (0.73-1.88) 0.62 (0.39-0.97) 0.87 (0.65-1.16)
DDAH2 c.531 A>C (rs805304)
co-dominant
A/A 1 1 1 1
A/C 1.13 (0.80-1.59) 0.79 (0.57-1.10) 1.04 (0.75-1.44) 0.97 (0.80-1.17)
C/C 1.17 (0.73-1.86) 0.91 (0.60-1.37) 1.13 (0.72-1.77) 1.05 (0.82-1.36)
dominant
A/A 1 1 1 1
A/C + C/C 1.14 (0.82-1.58) 0.82 (0.60-1.12) 1.06 (0.77-1.44) 0.99 (0.83-1.19)
 recessive
A/A + A/C 1 1 1 1
C/C 1.09 (0.72-1.65) 1.04 (0.73-1.50) 1.10 (0.74-1.65) 1.07 (0.86-1.35)
DDAH2 c.662 G>C (rs9267551)
dominant
G/G 1 1 1 1
G/C + C/C 1.05 (0.52-2.14) 1.08 (0.67-1.73) 1.20 (0.68-2.13) 1.11 (0.80-1.53)
(P > 0.05). The genotype distribution of all four variations except 
for DDAH2 c.531 A > C was significantly different in the three 
ethnic groups and the minor allele frequency (MAF) was lower 
in the Han group than in the Kazakh and Uygur groups.
Association between gene variation and hypertension
To evaluate associations between gene variation (DDAH1 -396 
4N del > ins, c.17 G > C, DDAH2 c.531 A > C and c.662 G > C) 
and hypertension, we performed logistic regression analy-
sis in accordance with three inheritance models: co-dominant, 
dominant and recessive. The results showed that there was no 
significant difference between hypertension patients and con-
trols, irrespective of the ethnic factor. 
Next, we assessed the effect of gene variation on hyperten-
sion in an ethnicity-specific case-control analysis. The G/C gen-
otype of rs3087894 (c. 17 G > C) in DDAH1 was a risk factor 
for hypertension in the Kazakh group in the co-dominant model 
(G/C versus G/G) (OR = 1.39; 95% CI = 1.02-1.88; P < 0.05) and 
the same result was obtained in the dominant model (G/C + C/C 
versus G/G) (OR = 1.38; 95% CI = 1.03-1.84; P < 0.05). In con-
trast, the C/C genotype of rs3087894 seemed to be a protective 
factor against hypertension in the Uygur group in the recessive 
Association between variation in the genes DDAH1 and DDAH2 and hypertension among Uygur, Kazakh and Han ethnic groups in China | ORIGINAL ARTICLE
Sao Paulo Med J. 2016; 134(3):205-10     209
model (C/C vs. G/G + G/C) (OR = 0.62; 95% CI = 0.39-0.97; 
P < 0.05), whereas there were no differences between patients 
and controls in the Han group (P > 0.05). No significant differ-
ence was observed in relating to the other three gene variation. 
The logistic regression and OR results, for possible associations 
between hypertension and gene variation are shown in Table 3. 
Similar findings for rs3087894 were also observed after adjusting 
the variable for the age covariate (Table 4).
DISCUSSION
To our knowledge, this was the first investigation of an associa-
tion between variation in the genes DDAH1 and DDAH2 and 
hypertension in a multi-ethnic Chinese population. The main 
finding from this study was that it demonstrated that the C-allele 
of rs3087894 in DDAH1 is a risk factor for hypertension in the 
Kazakh group but a protective factor in the Uygur group. In addi-
tion, we did not find any genotype of DDAH1 and DDAH2 asso-
ciated with hypertension in the Han group.
DDAH may play a crucial role in blood pressure regulation 
through clearance of ADMA, which inhibits NO synthase, thus 
having implications with regard to development of atherosclero-
sis.22 Some studies, both on animals and on humans, have dem-
onstrated that DDAH activity has a critical role in regulating NO 
synthesis in vivo. Hu et al. found that plasma and tissue ADMA 
levels in DDAH1 knockout mice were several times higher than 
in wild-type mice.23 In human research, previous studies have 
shown that more than 70% of the clearance of ADMA was due to 
DDAH activity and that genetic variation in DDAH1 was related 
to ADMA levels.24,25 These studies have shown that there could 
be functional variants in DDAH genes and that this is likely to 
affect the risk of vascular events.18 Ding et al. found that DDAH1 
polymorphism (-396 4N del>ins) in the promoter region was 
associated with increased risk of thrombosis, stroke and coro-
nary heart disease (CHD) in Han groups in China.19 Maas et al. 
found that the -1151 A/C and -449 G/C polymorphisms in the 
DDAH2 promoter region were associated with increased preva-
lence of hypertension.26
In the present study, we hypothesized that genetic varia-
tion in DDAH1 (-396 4N del > ins and c.17 G > C) and DDAH2 
(c.531 A > C and c.662 G > C) would present an association with 
hypertension, and we tested this in three ethnic groups. Because 
of the different genetic backgrounds, the genotype distribution of 
all four variations except for DDAH2 c.531 A > C was signifi-
cantly different between the three ethnic groups, and MAF was 
lower in the Han group than in the Kazakh and Uygur groups. 
Our study highlighted conflicting results for rs3087894 in 
DDAH1 in the three ethnic groups. We found that the C-allele 
of rs3087894 was a risk factor for hypertension in the Kazakh 
group (G/C versus G/G: OR = 1.39; 95% CI = 1.02-1.88; G/C + 
C/C versus G/G: OR = 1.38; 95% CI = 1.03-1.84; P < 0.05) but a 
protective factor in the Uygur group (C/C versus G/G + G/C: OR 
= 0.62; 95% CI = 0.39 - 0.97; P < 0.05). This was not a significant 
factor in the Han group (P > 0.05). 
The Uygur, Kazakh and Han groups are the three main ethnic 
groups living in the Xinjiang area, and they have total different 
genetic background, lifestyle and eating habits. Han individuals 
in this area have usually migrated from other provinces of China 
and have the typical way of life of the Han people. The Uygurs 
and Kazakhs are natives of Xinjiang. Uygurs are mainly engaged 
in farming and trade, but most Kazakhs still live a nomadic life. 
Moreover, Kazakhs have the highest incidence of hypertension 
among these three ethnic groups, while Uygurs are the contrary. 
In our study, we found that the C-allele of rs3087894 in 
DDAH1 plays conflicting roles in these three ethnic groups. 
The  mechanisms of this association need further investiga-
tion. The most possible explanation for the discrepancies lies 
within  differences in linkage-disequilibrium structure between 
these ethnic backgrounds. Differences in gene-gene or gene-
environment interactions in relation to the development of 
hypertension in these ethnic groups may also contribute towards 
the discrepancies. Lastly, the small sample size may also had had 
a certain degree of influence on the research results. Further 
research, specifically large-scale prospective cohort studies 
and further gene linkage-disequilibrium investigations, will be 
needed in order to confirm these findings.
CONCLUSION
We identified that rs3087894 in DDAH1 was significantly associ-
ated with hypertension and showed conflicting results in differ-
ent ethnic groups. This is therefore a candidate for further studies 
with the aim of helping to ascertain the mechanisms of hyperten-
sion in different populations.
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